BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launched in 1992, will need fewer women than originally estimated for completion. Although planned for 16,000 women, the trial now has more than 12,000 enrolled, and needs only another 1,000 for completion, which is expected next year.
The purpose of the trial, being conducted by the NCI-sponsored National Surgical Adjuvant Breast and Bowel Project (NSABP) is to determine whether tamoxifen(Drug information on tamoxifen) (Nolvadex) can prevent breast cancer in women at increased risk of the disease.
Because women who have volunteered for the study have had a much greater underlying risk of breast cancer than anticipated, the study will be able to get the answers it needs with fewer volunteers. In addition, the women who have volunteered are so committed that they are not dropping out at the normal rate.